SMTI Earnings Date: Nov 11, 2026 (Estimated) — Sanara MedTech Inc.
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is SMTI's next earnings date?
Sanara MedTech Inc. (SMTI) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.06 on revenue of $29.7M.
How did SMTI do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Sanara MedTech Inc. posted EPS of -$0.05 versus the -$0.03 estimate, a miss of 0.0%. Revenue was $28.1M against a $28.9M estimate. The stock's 1-day post-earnings move was +0.4%.
How much does SMTI stock move after earnings?
SMTI beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.5% (up or down) in the day after earnings.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.03 | -0.05 | +0.00% | $28.1M | ❌ Miss | +0.38% | -0.73% | +2.28% |
| 2026-05-11 | Q1 2026 | -0.18 | 0.05 | +127.78% | $27.8M | ✅ Beat | +13.43% | +21.48% | +27.58% |
| 2026-03-24 | Q4 2025 | 0.11 | 0.09 | -18.18% | $27.5M | ❌ Miss | -1.42% | -5.73% | +8.83% |
| 2025-11-12 | Q3 2025 | -0.23 | 0.09 | +139.13% | $26.3M | ✅ Beat | -24.71% | -25.46% | -14.05% |
| 2025-08-13 | Q2 2025 | -0.33 | -0.23 | +30.30% | $25.8M | ✅ Beat | +16.20% | +12.34% | +28.43% |
| 2025-03-25 | Q4 2024 | -0.19 | -0.18 | +5.26% | $26.3M | ✅ Beat | -12.58% | -13.51% | -15.33% |
| 2024-08-12 | Q2 2024 | -0.21 | -0.41 | -95.24% | $20.2M | ❌ Miss | -0.18% | +16.32% | +19.55% |
| 2024-05-13 | Q1 2024 | -0.07 | -0.21 | -200.00% | $18.5M | ❌ Miss | -6.81% | -2.90% | -1.37% |
Showing last 8 quarters.